Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
186 studies found for:    "Neurofibroma"
Show Display Options
Rank Status Study
1 Completed Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma;   Neurofibromatoses
Intervention: Drug: RAD001: Everolimus
2 Recruiting Natural History Study of Patients With Neurofibromatosis Type I
Conditions: Neurofibromatosis Type 1;   Malignant Peripheral Nerve Sheath Tumor;   Plexiform Neurofibroma;   Optic Glioma;   Neurofibroma
Intervention:
3 Completed
Has Results
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Conditions: Neurofibroma, Plexiform;   Neurofibromatosis Type I
Interventions: Drug: tipifarnib;   Other: placebo
4 Completed
Has Results
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Conditions: Neurofibromatosis 1;   Neurofibroma, Plexiform
Intervention: Drug: Pirfenidone
5 Completed Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Conditions: Neurofibromatosis Type I;   Plexiform Neurofibroma
Interventions: Drug: Nexavar (BAY 43-9006) (Sorafenib);   Drug: Toxicity, Pharmacokinetics;   Drug: Pharmacodynamics;   Drug: Radiographic Evaluation;   Drug: QOL assessment, Neuropsychological;   Drug: Bony Toxicity
6 Active, not recruiting Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
Conditions: NF1;   Neurofibromatosis;   Plexiform Neurofibromas
Intervention: Drug: Cabozantinib
7 Active, not recruiting Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Neurofibromas
Intervention: Drug: Tasigna
8 Active, not recruiting Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Conditions: Neurofibromatosis;   Neurofibromas
Intervention: Drug: Gleevec
9 Completed Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Conditions: Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention: Drug: Ranibizumab
10 Suspended
Has Results
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Conditions: Neurofibromatosis;   NF1;   Plexiform Neurofibromas
Intervention: Drug: Sutent®/Sunitinib
11 Recruiting Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Conditions: Cutaneous Neurofibromas;   Neurofibromatosis Type 1;   Plexiform Neurofibromas
Intervention: Procedure: Skin Biopsy
12 Active, not recruiting
Has Results
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma;   Spinal Cord Neurofibroma
Intervention: Drug: Cediranib Maleate
13 Completed Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Conditions: Neurofibromas;   Neurofibromatosis Type 1
Intervention:
14 Completed Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
Conditions: Tuberous Sclerosis;   Neurofibromatoses;   Angiofibroma;   Neurofibroma
Interventions: Drug: Skincerity;   Drug: Skincerity plus sirolimus/rapamycin;   Drug: Skinercity plus sirolimus/rapamycin
15 Terminated Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas
Condition: Neurofibroma
Intervention: Drug: LS11
16 Recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Selumetinib
17 Recruiting Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Conditions: Neurofibromatosis 1;   Plexiform Neurofibromas
Intervention:
18 Recruiting Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibromas
Intervention: Other: Acceptance and Commitment Therapy (ACT)
19 Unknown  First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas
Condition: Cutaneous Neurofibromas
Intervention: Procedure: Erbium-YAG laser vaporization
20 Completed Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
Conditions: Neurofibromatosis;   Neurofibromatosis I;   Neurofibromatosis 2;   Schwannomatosis
Intervention: Behavioral: The Relaxation Response Resiliency Program (3RP) via Skype

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years